Aurobindo Pharma shares gain after its arm gets USFDA’s final approval for Plerixafor Injection

Aurobindo Pharma's wholly-owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial. This injection is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mozobil Injection, 24 mg/1.2 mL (20 mg/mL) of Genzyme Corporation. The product is scheduled to be launched in July FY24. According to IQVIA, the approved product is estimated to have a market size of around $210 million for the twelve months ending in May 2023. 

Today, the stock opened at Rs 775.45, with a high and low of Rs 791.40 and Rs 775.45. Shares closed at Rs 788.50, up by 0.43% from its previous close of Rs 785.15. The stock has a fresh 52-week high of Rs 791.85 and a 52-week low of Rs 397.30. The current market cap of Aurobindo Pharma Ltd is Rs 46,201.26 crore.


Aurobindo Pharma maintains its position as one of the world's rapidly growing manufacturers of Active Pharmaceutical Ingredients (API), propelled by its focus on cost leadership, the ability to produce multiple products in the same manufacturing facilities, and expertise in various therapeutic domains. Through seamless vertical integration, its API business has been instrumental in driving profitability and growth in its formulations business.

The company's API business is backed by advanced research and development infrastructure, enabling the development of new products and efficient product delivery to the market. Aurobindo Pharma has successfully established a strong presence in critical therapeutic segments such as Central Nervous System (CNS), Cardiovascular (CVS), Anti-retroviral (ARV), Anti-diabetics, Gastroenterology, and Antibiotics. Moreover, it is actively developing a diversified pipeline in the high-margin specialty generic formulations segment. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet, and is subject to changes. Please consult an expert before making related decisions.